Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab

See also
Status	Clinical Trial	Phase
Terminated	`NCT03776864` - Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma	Phase 2
Recruiting	`NCT02356159` - Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation	Phase 1/Phase 2
Terminated	`NCT01929941` - An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies	Phase 1
Terminated	`NCT01699581` - Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant	Phase 2
Completed	`NCT00784537` - High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients	Phase 2/Phase 3
Completed	`NCT00333190` - CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation	N/A
Recruiting	`NCT05355051` - A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma	Phase 2
Completed	`NCT00520130` - Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System	Phase 1/Phase 2
Withdrawn	`NCT01316146` - Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)	Phase 1
Completed	`NCT02223052` - Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies	Phase 1
Completed	`NCT02581007` - Reduced Intensity Conditioning Transplant Using Haploidentical Donors	Phase 2
Terminated	`NCT01745913` - Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies	Phase 2
Recruiting	`NCT04665063` - A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma	N/A
Recruiting	`NCT02259556` - CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas	Phase 1/Phase 2
Completed	`NCT02003625` - Meloxicam vs Placebo for Mobilization	Phase 2
Terminated	`NCT01742793` - An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)	Phase 1
Completed	`NCT01402687` - SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT)	N/A
Terminated	`NCT00901303` - Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography (PET) Scan in Hodgkin's Lymphoma	N/A
Completed	`NCT00283439` - A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma	Phase 1/Phase 2
Completed	`NCT01272817` - Nonmyeloablative Allogeneic Transplant	N/A

NCT number	NCT02164006
Study type	Interventional
Source	TG Therapeutics, Inc.
Contact
Status	Completed
Phase	Phase 1
Start date	June 11, 2014
Completion date	May 2016

Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms